ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.89
+0.68%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.97
From 52W high−56.01%
Volume536907.00
Market cap$287.96M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$5.97
From 52W high
−56.01%
Volume
536907.00
Market cap
$287.96M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
P/E (TTM)
—
RSI (14)
24.9
MomentumView details →
1D Return
+0.68%
YTD Return
+36.95%
SummaryUpdated Jun 1, 2026
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company founded in 2019 and headquartered in San Diego, California. The company specializes in developing innovative cell-based therapies using natural killer (NK) cells to treat both autoimmune diseases and various forms of cancer. Since its incorporation, Artiva has focused on advancing a pipeline of off-the-shelf and engineered NK cell therapies, with its lead candidate AB-101 currently in clinical development for multiple indications including lupus nephritis, rheumatoid arthritis, and B-cell lymphomas.
Similar companies
Latest newsMore news →
Artiva Biotherapeutics presented updated clinical data for its AlloNK® therapy in Sjögren's disease at the 17th International Symposium on Sjögren's Disease (ISSjD 2026).19d agoArtiva Biotherapeutics announced that updated clinical data for its AlloNK (AB-101) allogeneic NK cell therapy combined with rituximab in Sjögren's disease patients will be presented orally at the 17th International Symposium on Sjögren's Disease in Paris.27d agoArtiva Biotherapeutics, Inc. elected Brian Daniels, M.D. and Laura Stoppel, Ph.D. as Class II directors effective September 8, 2026.38d ago